Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal second quarter ended Sept. 30 was 4 Indian paise per share, a decrease of 80.3% from 19 paise per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 266,250 rupees, a decline of 80.2% from 1.3 million rupees in the year-earlier period.
The normalized profit margin dropped to 0.3% from 1.4% in the year-earlier period.
Total revenue increased 7.2% year over year to 104.6 million rupees from 97.6 million rupees, and total operating expenses climbed 9.1% from the prior-year period to 100.2 million rupees from 91.9 million rupees.
Reported net income decreased 93.2% from the prior-year period to 100,000 rupees, or 1 paise per share, from 1.5 million rupees, or 21 paise per share.
As of Nov. 13, US$1 was equivalent to 66.19 Indian rupees.